VD5K58YKDZ Association Between Weight Lost and Diabetes Resolution After Bariatric Surgery With Preoperative GLP-1 Agonist Use

Document Type

Abstract

Publication Date

6-1-2025

Abstract

Ellen Pekar University of Pennsylvania; John Fam Tower Health/Drexel University; Roshan Shaik Tower Health Introduction: GLP1 agonists have rapidly emerged as effective tools for management of obesity and obesity related complications. With the shared mechanism between bariatric surgery and GLP-1 agonists, it would lead to reason that a combination approach between surgery and medical management would lead to increased postoperative weight loss in the long term. This study will aim to evaluate if there is a benefit postoperatively from preoperative GLP-1 use in bariatric surgery patients. Method: Retrospective study looking at all patients from a single bariatric center undergoing primary bariatric surgery (sleeve, SADI, RYGB) from 2021- July 2024. Data on BMI at different time points pre/postoperatively, medication use from time of program until weight loss surgery, type of bariatric surgery performed, diabetes status, A1c pre and post op, complications, and readmissions was collected. Results: Preliminary results were collected from 60 patients. 30 (50%) patients received a GLP-1 agonist preoperatively for at least 6 weeks. For the GLP1 group there was a 11.5 ± 14.7 BMI change at 6 months postoperatively vs a 12.6 ± 17.3 change in the control group (p=.28). There was no statistically significant BMI reduction between groups. There was no difference in perioperative complications between groups (p=0.36). There was no statistically significant rate of diabetes resolution between groups (p=1.59). Conclusion: From preliminary results there is no additional postoperative benefit in regards to weight loss or diabetes resolution from addition of GLP1 agonist preoperatively. Further analysis will be done on the data in order to increase sample size and accuracy. Further studies are required in order to evaluate the long term effects of GLP-1 agonists on bariatric surgery patients.

Publication Title

Surgery for Obesity and Related Diseases

Volume

21

Issue

6 Supplement

First Page

S86

Last Page

S86

Comments

American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting 2025 held 2025-04-12 to 2025-04-15 in Chicago, IL, USA.

Link to Full Text

Open Access

Share

COinS